An Open-Label, Single-Arm, Maintenance Study to Demonstrate Long-Term Efficacy and Safety of CT-P10 in Patients With Rheumatoid Arthritis Who Were Treated With Rituximab (MabThera or CT-P10) in Study CT-P10 1.1

Trial Profile

An Open-Label, Single-Arm, Maintenance Study to Demonstrate Long-Term Efficacy and Safety of CT-P10 in Patients With Rheumatoid Arthritis Who Were Treated With Rituximab (MabThera or CT-P10) in Study CT-P10 1.1

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Rituximab (Primary) ; Folic acid; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celltrion
  • Most Recent Events

    • 09 Jun 2017 Results published in the BioDrugs
    • 25 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Aug 2014 Planned End Date changed from 30 Sep 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top